Orchestra BioMed Holdings (OBIO) Cost of Revenue: 2022-2025
Historic Cost of Revenue for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Sep 2025 value amounting to $49,000.
- Orchestra BioMed Holdings' Cost of Revenue fell 27.94% to $49,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $197,000, marking a year-over-year increase of 2.07%. This contributed to the annual value of $204,000 for FY2024, which is 9.68% up from last year.
- As of Q3 2025, Orchestra BioMed Holdings' Cost of Revenue stood at $49,000, which was up 6.52% from $46,000 recorded in Q2 2025.
- In the past 5 years, Orchestra BioMed Holdings' Cost of Revenue ranged from a high of $68,000 in Q3 2024 and a low of $34,000 during Q1 2024.
- In the last 3 years, Orchestra BioMed Holdings' Cost of Revenue had a median value of $46,000 in 2025 and averaged $48,091.
- Per our database at Business Quant, Orchestra BioMed Holdings' Cost of Revenue surged by 65.85% in 2024 and then dropped by 27.94% in 2025.
- Over the past 4 years, Orchestra BioMed Holdings' Cost of Revenue (Quarterly) stood at $53,000 in 2022, then decreased by 11.32% to $47,000 in 2023, then rose by 23.40% to $58,000 in 2024, then fell by 27.94% to $49,000 in 2025.
- Its Cost of Revenue stands at $49,000 for Q3 2025, versus $46,000 for Q2 2025 and $44,000 for Q1 2025.